

## HOW IS DISCLOSURE EFFECTED?

## FURTHER INFORMATION ON THE SUBJECT:

To achieve a high degree of transparency, **disclosure** should take place **individually**, i.e. naming the recipients in person. This requires the consent of the persons or organizations concerned to such disclosure. For this purpose, the cooperation agreements between the companies and these professional persons and organizations must be **supplemented by suitable consent clauses**. The companies are currently in contact with these stakeholders for that reason.

[www.scienceindustries.ch/pcc](http://www.scienceindustries.ch/pcc)



Pharma Cooperation Code (PCC)

Disclosure from 2016

## WHAT ABOUT?

## WHAT COMMITMENT HAVE THE PCC SIGNATORY COMPANIES MADE?

## WHICH BENEFITS ARE DISCLOSED?

On 24 June 2013, the European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted the new EFPIA Disclosure Code.

On that basis, **scienceindustries** as the responsible member association of EFPIA in Switzerland drew up the **Pharma Cooperation Code (PCC)** which entered into force in January 2014. The partner associations Inter-generika, Interpharma and vips have also subscribed to the PCC.

**With effect from 2016, the signatory companies will disclose each year on their websites accessible to the public the pecuniary benefits** which they granted in the previous year (beginning with 2015) to professionals (primarily physicians and pharmacists) as well as health-care organizations (in particular hospitals and research institutes).

The term **pecuniary benefits** as defined by the PCC means remuneration granted either directly or indirectly in connection with pharmaceuticals for human medicine available on prescription only. The disclosure includes payments made e.g. for consultancy and the provision of services, financial support for research and development in the healthcare sector and cost contributions for the attendance of professionals at events.

### **There are few exceptions from the obligation to disclose pecuniary benefits, e.g.:**

- normal commercial compensation for professionals when pharmaceuticals are ordered and delivered
- delivery of pharmaceutical samples without payment to professionals within the limits of the official recommendations
- information and training materials of modest value
- payment for meals (including beverages)

